Core Viewpoint - Rosen Law Firm is reminding investors who purchased Akero Therapeutics, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Akero common stock between September 13, 2022, and October 9, 2023, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 25, 2024 [1][4]. Group 2: Case Allegations - The lawsuit alleges that Akero made false and misleading statements regarding the SYMMETRY study, which tested its lead product candidate, efruxifermin (EFX), in patients with Non-alcoholic Steatohepatitis (NASH) induced cirrhosis [3]. - Key allegations include that approximately 20% of patients in the SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline, which was not disclosed [3]. - The lawsuit claims that the results from these patients were improperly included in the study, potentially skewing the results and increasing the risk of failing to meet the primary endpoint [3]. - It is also alleged that Akero did not align the study with U.S. FDA guidance, further misrepresenting the trial's nature and its potential success in supporting a new drug application [3].

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for potential violations of the federal securities laws. If you suffered a loss in Akero securities, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci J ...

Core Viewpoint - A securities class action lawsuit has been filed against Akero Therapeutics, Inc. for failing to disclose material information during the Class Period, which has led to significant stock price declines following the revelation of study results [1][2][4]. Group 1: Lawsuit Details - Investors have until June 25, 2024, to file lead plaintiff applications in the lawsuit against Akero Therapeutics [1]. - The lawsuit is pending in the United States District Court for the Northern District of California [1]. - The case is identified as Klobus v. Akero Therapeutics, Inc., No. 24-cv-02534 [4]. Group 2: Allegations Against Akero - Akero and its executives are accused of not disclosing that approximately 20% of patients in the SYMMETRY study had cryptogenic cirrhosis, which misrepresented the study's results [3]. - The company allegedly introduced confounding factors into the SYMMETRY study's design, which could materially influence the study's outcomes [3]. - It is claimed that the SYMMETRY study did not align with FDA guidance for testing drugs in treating NASH cirrhotics, leading to misrepresentation of the trial's nature and potential success [3]. Group 3: Market Reaction - On October 10, 2023, Akero disclosed the SYMMETRY study's 36-week results, resulting in a stock price drop of $30.39 per share, followed by an additional decline of $3.11 per share on the next day, totaling a nearly 70% decrease from the previous closing price of $48.54 [4].

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Akero Therapeutics, Inc. ("Akero") (NASDAQ:AKRO) for potential violations of the federal securities laws. If you suffered a loss in Akero securities, and wish to participate, learn more, or discuss the issues surrounding the investigation, please contact attorneys at (914) 733-7256 or via email to Andrea Farah (afarah@lowey.com) or Vincent R. Cappucci Jr. ...

NEW YORK, May 22, 2024 /PRNewswire/ --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive (the "Class Period"), of the important June 25, 2024 lead plaintiff deadline.SO WHAT: If you purchased Akero common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

RADNOR, Pa., May 22, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO). The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects.  As a ...

Core Viewpoint - A securities class action lawsuit has been filed against Akero Therapeutics, alleging violations of federal securities laws due to misleading statements and omissions regarding the company's business and prospects, resulting in significant investor losses [1][2]. Group 1: Company Overview - Akero Therapeutics is a clinical stage drug development company that has not yet generated any revenues as the FDA has not approved any of its drug candidates for sale [2]. - The company raised over $577 million through two secondary stock offerings and one at-the-market stock offering during the Class Period to finance its operations [2]. Group 2: Class Period and Financial Activities - The Class Period began on September 13, 2022, when Akero reported positive results from its Phase 2b HARMONY study for its lead product candidate, EFX, which is aimed at treating Nonalcoholic steatohepatitis (NASH) [3]. - Following the positive report, Akero conducted a secondary offering, selling over 8.8 million shares at $26 per share, raising approximately $230 million [3]. Group 3: Allegations of Misconduct - Throughout the Class Period, Akero allegedly misled investors about the patient population in its SYMMETRY study, claiming it was limited to patients with NASH-induced cirrhosis, while approximately 20% of the tested patients had not been confirmed to have NASH [4]. - On October 10, 2023, Akero disclosed disappointing interim data from its Phase 2b SYMMETRY trial, revealing that the changes in fibrosis were not statistically significant, leading to a stock price drop of $30.39 per share, or 62.61%, closing at $18.15 [5].

NEW ORLEANS, May 17, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until June 25, 2024 to file lead plaintiff applications in a securities class action lawsuit against Akero Therapeutics, Inc. (NasdaqGS: AKRO), if they purchased or otherwise acquired the Company's shares between September 13, 2022 and October 9, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California. ...

RADNOR, Pa., May 16, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Akero Therapeutics, Inc. ("Akero") (NASDAQ: AKRO). The action charges Akero with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a re ...

NEW YORK, May 16, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. ("Akero" or the "Company") (NASDAQ: AKRO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Akero and certain of its officers ...